Results 51 to 60 of about 729,544 (396)

Tumor necrosis factor alpha gene polymorphism in Serbian patients with sarcoidosis [PDF]

Srpski Arhiv za Celokupno Lekarstvo, 2013
Introduction. Sarcoidosis is a multisystemic disease of unknown etiology. Genetic factors play a considerable role in the onset of the disease. Tumor necrosis factor alpha (TNF-α) is a proinflammatory cytokine which plays an important role in the ...
Rađenović-Petković Tatjana, Pejčić Tatjana, Videnović-Ivanov Jelica, Jevtović-Stoimenov Tatjana, Janković Irena, Nastasijević-Borovac Desa, Radojković Danijela   +6 more
doaj   +1 more source

Tumor Necrosis Factor Alpha: Implications of Anesthesia on Cancers

Cancers, 2023
Cancer remains a major public health issue and a leading cause of death worldwide. Despite advancements in chemotherapy, radiation therapy, and immunotherapy, surgery is the mainstay of cancer treatment for solid tumors. However, tumor cells are known to disseminate into the vascular and lymphatic systems during surgical manipulation.
Wei-Cheng Tseng, Hou-Chuan Lai, Yi-Hsuan Huang, Shun-Ming Chan, Zhi-Fu Wu   +4 more
openaire   +2 more sources

Cis‐regulatory and long noncoding RNA alterations in breast cancer – current insights, biomarker utility, and the critical need for functional validation

Molecular Oncology, EarlyView.
The noncoding region of the genome plays a key role in regulating gene expression, and mutations within these regions are capable of altering it. Researchers have identified multiple functional noncoding mutations associated with increased cancer risk in the genome of breast cancer patients.
Arnau Cuy Saqués, Aracele Martinez‐Mendez, John Crown, Alex Eustace   +3 more
wiley   +1 more source

Potential therapeutic targeting of BKCa channels in glioblastoma treatment

Molecular Oncology, EarlyView.
This review summarizes current insights into the role of BKCa and mitoBKCa channels in glioblastoma biology, their potential classification as oncochannels, and the emerging pharmacological strategies targeting these channels, emphasizing the translational challenges in developing BKCa‐directed therapies for glioblastoma treatment.
Kamila Maliszewska‐Olejniczak, Karolina Pytlak, Sandra Jaworowska, Bogusz Kulawiak, Piotr Bednarczyk   +4 more
wiley   +1 more source

The relationships between eicosanoid production and pro-inflammatory cytokines [PDF]

, 2001
Explores alternate strategies that may alter inflammatory cytokine production, particularly tumour necrosis factor α [tumor necrosis factor-alpha], and therefore provide a possible treatment for rheumatoid arthritis.Thesis (Ph.D.) -- University of ...
Penglis, Peter Savas
core  

Pancreatic cancer cachexia: a review of mechanisms and therapeutics. [PDF]

, 2014
Over the last decade, we have gained new insight into the pathophysiology of cachexia associated with pancreatic cancer. Unfortunately, its treatment is complex and remains a challenge.
Andrew Eugene Hendifar, Andrew Eugene Hendifar, Carlyn Rose Tan, Laith eJamil, Nick eNissen, Patrick eYaffee, Richard eTuli, Simon eLo, Stephen J Pandol   +8 more
core   +2 more sources

Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation

Journal of Experimental Medicine, 1993
We have examined the mechanism of thalidomide inhibition of lipopolysaccharide (LPS)-induced tumor necrosis factor alpha (TNF- alpha) production and found that the drug enhances the degradation of TNF-alpha mRNA.
P. Frindt, Kendall A. Smith, G. Kaplan
semanticscholar   +1 more source

TREX1, a predator for treating MSI‐H tumors?

Molecular Oncology, EarlyView.
Immunotherapy benefits many patients; yet, some with MSI‐H tumors remain unresponsive despite their high immunogenicity. Xu et al. reveal that TREX1 enables immune evasion by degrading cytosolic DNA and suppressing cGAS–STING–IFN‐I signaling. TREX1 loss restores DNA sensing, increases CD8+ T and NK cell infiltration, and boosts antitumor immunity ...
Elena Benidovskaya, Joséphine Deneft, Marc Van den Eynde   +2 more
wiley   +1 more source

Tumor necrosis factor-alpha inhibitor treatment for sarcoidosis

Therapeutics and Clinical Risk Management, 2008
José Luis Callejas-Rubio, Lourdes López-Pérez, Norberto Ortego-CentenoUnit of Autoimmune Systemic Diseases, Hospital Clinico San Cecilio, Granada, SpainAbstract: Sarcoidosis is a chronic multisystem disease of unknown ...
José Luis Callejas-Rubio, Lourdes López-Pérez, Norberto Ortego-Centeno   +2 more
doaj  

ATF4‐mediated stress response as a therapeutic vulnerability in chordoma

Molecular Oncology, EarlyView.
We screened 5 chordoma cell lines against 100+ inhibitors of epigenetic and metabolic pathways and kinases and identified halofuginone, a tRNA synthetase inhibitor. Mechanistically halofuginone induces an integrated stress response, with eIF2alpha phosphorylation, activation of ATF4 and its target genes CHOP, ASNS, INHBE leading to cell death ...
Lucia Cottone, James Dunford, Eleanor Calcutt, Vicki Gamble, Filiz Senbabaoglu Aksu, Lorena Ligammari, Georgina Wherry, Giorgia Gaeta, John C. Christianson, Adrienne M. Flanagan, Udo Oppermann, Adam P. Cribbs   +11 more
wiley   +1 more source